Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Citius Pharmaceuticals is a biotechnology business based in the US. Citius Pharmaceuticals stocks (CTXR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.16 – an increase of 0.4% over the previous week. Citius Pharmaceuticals employs 15 staff and has a market cap (total outstanding stock value) of $128.9 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
Global Trading
| Latest market close | $0.90 |
|---|---|
| 52-week range | $0.88 - $4.56 |
| 50-day moving average | $1.46 |
| 200-day moving average | $1.71 |
| Wall St. target price | $6.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.20 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $0.9016 from 2022-05-18
| 1 week (2022-05-09) | -4.26% |
|---|---|
| 1 month (2022-04-19) | -30.91% |
| 3 months (2022-02-17) | -49.63% |
| 6 months (2021-11-15) | N/A |
| 1 year (2021-05-19) | -58.83% |
|---|---|
| 2 years (2020-05-19) | 12.70% |
| 3 years (2019-05-17) | 1.38 |
| 5 years (2017-05-19) | 124.28% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -17.82% |
| Return on equity TTM | -32.1% |
| Profit margin | 0% |
| Book value | $0.85 |
| Market capitalisation | $128.9 million |
TTM: trailing 12 months
We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months.
Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.
Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $0.88 up to $4.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.4113. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. .
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of online gaming stocks.
Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
Everything we know about the Wytec International IPO, plus information on how to buy in.
Here are some of the best stocks for inflation periods to reduce the negative impacts of inflation on your portfolio.
Choose from many account and investment types to invest in global markets, but expect to pay high commissions with HSBC InvestDirect, which doesn’t have an app.
Our Flahmingo review tells you how to buy fractional shares of some of your favourite US companies with as little as $1.
Steps to owning and managing EXPD stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PRU stock, with 24-hour and historical pricing before you buy.
